Article · 2018
“Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas”
Publication
- Title
- “Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas”
- Author
- M. Kazim Panjwani (Columbia College, Class of 2011)
- Form
- Article
- First published
- 2018
- Publisher
- Molecular Therapy – Oncolytics
Complete works of M. Kazim Panjwani (8)
- 2016 “Feasibility and Safety of RNA-Transfected CD20-Specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma” · Molecular Therapy
- 2018 “Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas” · Molecular Therapy – Oncolytics this record
- 2020 “Establishing a Model System for Evaluating CAR T Cell Therapy Using Dogs with Spontaneous Diffuse Large B Cell Lymphoma” · Oncoimmunology
- 2021 “Human Cytomegalovirus Expands a CD8+ T Cell Population with Loss of BCL11B Expression and Gain of NK Cell Identity” · Science Immunology
- 2021 “Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset” · The Journal of Immunology
- 2023 “Immune Escape after Allogeneic Hematopoietic Cell Transplantation in Pediatric Acute Myeloid Leukemia” · Blood Advances
- 2024 “Polygenic Polymorphism Is Associated with NKG2A Repertoire and Influences Lymphocyte Phenotype and Function” · Blood Advances
- 2024 “Single-Cell Profiling Aligns CD56bright and Cytomegalovirus-Induced Adaptive Natural Killer Cells to a Naïve-Memory Relationship” · Frontiers in Immunology
Cite this record
Panjwani, M. Kazim. “Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas”. Molecular Therapy – Oncolytics, 2018.
Foundation record: https://philolexianfoundation.org/members/panjwani-m-kazim-cc-2011/checkpoint-blockade-reverses-anergy-in-il-13r-2-humanized-scfv-based-car-t-cells-2018.html